Okogen, Inc., a clinical-stage biotechnology company developing innovative therapies for infectious diseases, announced on October 6, 2026, that the Central Drugs Standard Control Organisation (CDSCO), India’s national drug regulatory authority, has authorized the EMERALD study. This Phase 1/2 clinical trial will evaluate Treyegen™ (OKG-0303) for the treatment of acute infectious conjunctivitis. The authorization marks a significant step forward for Okogen’s lead ophthalmology program and provides the first regulatory clearance for the company’s host-directed antiviral platform in a clinical setting.
The EMERALD study is designed to enroll more than 300 patients and will assess safety, pharmacokinetics, virologic and microbiologic activity, and clinical efficacy. Data from the trial are expected later this year. Acute infectious conjunctivitis, commonly known as pink eye, is a highly contagious condition that can be caused by both viruses and bacteria. Current treatments often require physicians to make a presumptive diagnosis and choose between antiviral or antibacterial therapies, which can lead to delays or inappropriate use of antibiotics.
Treyegen™ (OKG-0303) is an investigational ophthalmic therapy that combines three active ingredients into a single formulation: ranpirnase, a host-directed antiviral; tobramycin, a broad-spectrum antibacterial; and oxymetazoline, which reduces ocular redness. This proprietary combination is designed to address the broad clinical presentation of acute infectious conjunctivitis with one therapy, potentially simplifying treatment decisions for physicians and offering a comprehensive option for patients. If successful, Treyegen™ could become the first single-agent treatment to target both viral and bacterial forms of the disease.
The CDSCO authorization is important because it allows Okogen to advance its lead candidate into clinical evaluation in a large patient population, generating data that could support future regulatory submissions. It also validates the company’s strategy of using ophthalmology as the initial proving ground for its ranpirnase-based platform. Okogen is developing ranpirnase therapies across four pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. Clinical insights and formulation expertise gained from the EMERALD study may accelerate progress in these other areas.
For more details on the authorization, including downloadable images and bios, click here. Okogen’s broader pipeline aims to apply its host-directed antiviral platform to address a range of infectious diseases. The company’s goal is to leverage clinical insights, formulation expertise, and manufacturing capabilities to build a portfolio of antiviral therapies. More information about Okogen is available at www.okogen.com. The EMERALD study’s outcomes will be closely watched as a test of the platform’s potential beyond conjunctivitis.
